Omnio is preparing for taking the company to the next phase
SWEDEN, 5th May, 2023 — Omnio AB, a private biopharmaceutical company developing recombinant plasminogen for chronic non-healing wounds, announces the inauguration of a new board of directors that brings together an outstanding team of seasoned executives in the biotech and life sciences industries. The board of directors comprises of Tomas Eriksson as Chairman of the […]
Omnio raises 1.5M EUR in successful series A funding
SWEDEN, 8th November, 2022 — Omnio AB, a private biopharmaceutical company developing recombinant plasminogen to heal chronic wounds announces a successful 1.5M EUR funding round. The funds will be allocated to develop a manufacturing process for the recombinant plasminogen drug product and conduct efficacy studies of the drug candidate in animal models for wound healing. […]
Omnio AB raises 5.5MSEK in fundraising round
SWEDEN, 6th December, 2021 — Omnio AB is developing new drug products based on the proinflammatory and immune regulatory effects of the serum protein plasminogen. During fall the company successfully raised 5.5MSEK in a new share issue and welcomed four new investors to the company. The added investments make it possible for the company to […]